Skip to main content
Top
Published in: Current HIV/AIDS Reports 3/2018

01-06-2018 | The Global Epidemic (SH Vermund, Section Editor)

Syringe Decriminalization Advocacy in Red States: Lessons from the North Carolina Harm Reduction Coalition

Authors: David H. Cloud, Tessie Castillo, Lauren Brinkley-Rubinstein, Manisha Dubey, Robert Childs

Published in: Current HIV/AIDS Reports | Issue 3/2018

Login to get access

Abstract

Purpose of Review

Syringe access programs (SAPs) are cornerstone harm reduction interventions for combatting the national opioid epidemic. The goal of this paper is to describe effective advocacy strategies for enacting syringe decriminalization legislation to foster the expansion of SAPs in high-need areas amidst political opposition.

Recent Findings

Decades or research shows that SAPs prevent the transmission of HIV among people who inject drugs (PWID) and are a cost-effective tool for linking PWID to medical care, health education, and social services. In the USA, state laws criminalizing distribution and possession of syringes impede the expansion of SAPs into areas where they are sorely needed.

Summary

In 2016, North Carolina became the first state to legalize SAPs with a Republican super majority. This paper distills strategies for community organizations seeking to advance syringe decriminalization legislation in politically conservative states with histories of prioritizing punitive sanctions over public health responses to drug use.
Literature
1.
go back to reference Zibbell JE, Iqbal K, Patel RC, Suryaprasad A, Sanders KJ, Moore-Moravian L, et al. Increases in hepatitis C virus infection related to injection drug use among persons aged ≤ 30 years-Kentucky, Tennessee, Virginia, and West Virginia, 2006–2012. MMWR Morb Mortal Wkly Rep. 2015;64(17):453–8.PubMedPubMedCentral Zibbell JE, Iqbal K, Patel RC, Suryaprasad A, Sanders KJ, Moore-Moravian L, et al. Increases in hepatitis C virus infection related to injection drug use among persons aged ≤ 30 years-Kentucky, Tennessee, Virginia, and West Virginia, 2006–2012. MMWR Morb Mortal Wkly Rep. 2015;64(17):453–8.PubMedPubMedCentral
2.
go back to reference Onofrey S, Aneja J, Haney GA, Nagami EH, DeMaria A, Lauer GM, et al. Underascertainment of acute hepatitis C virus infections in the US surveillance system a case series and chart review. Ann Intern Med. 2015;163(4):254–61.CrossRefPubMedPubMedCentral Onofrey S, Aneja J, Haney GA, Nagami EH, DeMaria A, Lauer GM, et al. Underascertainment of acute hepatitis C virus infections in the US surveillance system a case series and chart review. Ann Intern Med. 2015;163(4):254–61.CrossRefPubMedPubMedCentral
3.
go back to reference Rhea S, Fleischauer A, Foust E, Davies M. Hepatitis C in North Carolina two epidemics with one public health response. N C Med J. 2016;77(3):190–2.PubMed Rhea S, Fleischauer A, Foust E, Davies M. Hepatitis C in North Carolina two epidemics with one public health response. N C Med J. 2016;77(3):190–2.PubMed
7.
go back to reference Mathers BM, Degenhardt L, Bucello C, Lemon J, Wiessing L, Hickman M. Mortality among people who inject drugs: a systematic review and meta-analysis. Bull World Health Organ. 2013;91(2):102–23.CrossRefPubMedPubMedCentral Mathers BM, Degenhardt L, Bucello C, Lemon J, Wiessing L, Hickman M. Mortality among people who inject drugs: a systematic review and meta-analysis. Bull World Health Organ. 2013;91(2):102–23.CrossRefPubMedPubMedCentral
8.
9.
go back to reference Altice FL, Kamarulzaman A, Soriano VV, Schechter M, Friedland GH. Treatment of medical, psychiatric, and substance-use comorbidities in people infected with HIV who use drugs. Lancet. 2010;376(9738):367–87.CrossRefPubMedPubMedCentral Altice FL, Kamarulzaman A, Soriano VV, Schechter M, Friedland GH. Treatment of medical, psychiatric, and substance-use comorbidities in people infected with HIV who use drugs. Lancet. 2010;376(9738):367–87.CrossRefPubMedPubMedCentral
12.
go back to reference Gibson DR, Flynn NM, Perales D. Effectiveness of syringe exchange programs in reducing HIV risk behavior and HIV seroconversion among injecting drug users. AIDS. 2001;15(11):1329–41.CrossRefPubMed Gibson DR, Flynn NM, Perales D. Effectiveness of syringe exchange programs in reducing HIV risk behavior and HIV seroconversion among injecting drug users. AIDS. 2001;15(11):1329–41.CrossRefPubMed
13.
go back to reference Bastos FI, Strathdee SA. Evaluating effectiveness of syringe exchange programmes: current issues and future prospects. Soc Sci Med. 2000;51(12):1771–82.CrossRefPubMed Bastos FI, Strathdee SA. Evaluating effectiveness of syringe exchange programmes: current issues and future prospects. Soc Sci Med. 2000;51(12):1771–82.CrossRefPubMed
14.
go back to reference Heimer R, Khoshnood K, Bigg D, Guydish J, Junge B. Syringe use and reuse: effects of syringe exchange programs in four cities. J Acquir Immune Defic Syndr. 1998;18:S37–44.CrossRef Heimer R, Khoshnood K, Bigg D, Guydish J, Junge B. Syringe use and reuse: effects of syringe exchange programs in four cities. J Acquir Immune Defic Syndr. 1998;18:S37–44.CrossRef
15.
go back to reference Watters JK, Estilo MJ, Clark GL, Lorvick J. Syringe and needle exchange as HIV/AIDS prevention for injection drug users. JAMA. 1994;271(2):115–20.CrossRefPubMed Watters JK, Estilo MJ, Clark GL, Lorvick J. Syringe and needle exchange as HIV/AIDS prevention for injection drug users. JAMA. 1994;271(2):115–20.CrossRefPubMed
16.
go back to reference Wodak, A., Cooney, A., & World Health Organization. (2004). Effectiveness of sterile needle and syringe programming in reducing HIV. Wodak, A., Cooney, A., & World Health Organization. (2004). Effectiveness of sterile needle and syringe programming in reducing HIV.
17.
go back to reference Holtzman D, Barry V, Ouellet LJ, Des Jarlais DC, Vlahov D, Golub ET, et al. The influence of needle exchange programs on injection risk behaviors and infection with hepatitis C virus among young injection drug users in select cities in the United States, 1994–2004. Prev Med. 2009;49(1):68–73.CrossRefPubMed Holtzman D, Barry V, Ouellet LJ, Des Jarlais DC, Vlahov D, Golub ET, et al. The influence of needle exchange programs on injection risk behaviors and infection with hepatitis C virus among young injection drug users in select cities in the United States, 1994–2004. Prev Med. 2009;49(1):68–73.CrossRefPubMed
18.
go back to reference Clark AK, Wilder CM, Winstanley EL. A systematic review of community opioid overdose prevention and naloxone distribution programs. J Addict Med. 2014;8(3):153–63.CrossRefPubMed Clark AK, Wilder CM, Winstanley EL. A systematic review of community opioid overdose prevention and naloxone distribution programs. J Addict Med. 2014;8(3):153–63.CrossRefPubMed
19.
go back to reference Strathdee SA, Ricketts EP, Huettner S, Cornelius L, Bishai D, Havens JR, et al. Facilitating entry into drug treatment among injection drug users referred from a needle exchange program: results from a community-based behavioral intervention trial. Drug Alcohol Depend. 2006;83(3):225–32.CrossRefPubMed Strathdee SA, Ricketts EP, Huettner S, Cornelius L, Bishai D, Havens JR, et al. Facilitating entry into drug treatment among injection drug users referred from a needle exchange program: results from a community-based behavioral intervention trial. Drug Alcohol Depend. 2006;83(3):225–32.CrossRefPubMed
20.
go back to reference Strathdee SA, Celentano DD, Shah N, Lyles C, Stambolis VA, Macalino G, et al. Needle-exchange attendance and health care utilization promote entry into detoxification. Journal of Urban Health. 1999;76(4):448–60.CrossRefPubMedPubMedCentral Strathdee SA, Celentano DD, Shah N, Lyles C, Stambolis VA, Macalino G, et al. Needle-exchange attendance and health care utilization promote entry into detoxification. Journal of Urban Health. 1999;76(4):448–60.CrossRefPubMedPubMedCentral
21.
go back to reference Marx MA, Crape B, Brookmeyer RS, Junge B, Latkin C, Vlahov D, et al. Trends in crime and the introduction of a needle exchange program. Am J Public Health. 2000;90(12):1933–6.CrossRefPubMedPubMedCentral Marx MA, Crape B, Brookmeyer RS, Junge B, Latkin C, Vlahov D, et al. Trends in crime and the introduction of a needle exchange program. Am J Public Health. 2000;90(12):1933–6.CrossRefPubMedPubMedCentral
22.
go back to reference Galea S, Ahern J, Fuller C, Freudenberg N, Vlahov D. Needle exchange programs and experience of violence in an inner city neighborhood. J Acquir Immune Defic Syndr. 2001;28(3):282–8.CrossRefPubMed Galea S, Ahern J, Fuller C, Freudenberg N, Vlahov D. Needle exchange programs and experience of violence in an inner city neighborhood. J Acquir Immune Defic Syndr. 2001;28(3):282–8.CrossRefPubMed
24.
go back to reference The American Public Health Association. Policy Statement. Syringe and Needle Exchange and HIV Disease. The American Public Health Association. Policy Statement. Syringe and Needle Exchange and HIV Disease.
28.
go back to reference Wejnert C. Vital signs: trends in HIV diagnoses, risk behaviors, and prevention among persons who inject drugs—United States. MMWR Morb Mortal Wkly Rep. 2016;65:1336–42.CrossRefPubMed Wejnert C. Vital signs: trends in HIV diagnoses, risk behaviors, and prevention among persons who inject drugs—United States. MMWR Morb Mortal Wkly Rep. 2016;65:1336–42.CrossRefPubMed
29.
go back to reference Heller D, Paone D. Access to sterile syringes for injecting drug users in new York City: politics and perception (1984–2010). Substance Use & Misuse. 2011;46(2–3):140–9.CrossRef Heller D, Paone D. Access to sterile syringes for injecting drug users in new York City: politics and perception (1984–2010). Substance Use & Misuse. 2011;46(2–3):140–9.CrossRef
30.
go back to reference Des Jarlais DC, McKnight C, Goldblatt C, Purchase D. Doing harm reduction better: syringe exchange in the United States. Addiction. 2009;104(9):1441–6.CrossRefPubMed Des Jarlais DC, McKnight C, Goldblatt C, Purchase D. Doing harm reduction better: syringe exchange in the United States. Addiction. 2009;104(9):1441–6.CrossRefPubMed
31.
go back to reference Friedman SR, Southwell M, Bueno R, Paone D, Byrne J, Crofts N. Harm reduction—a historical view from the left. International Journal of Drug Policy. 2001;12(1):3–14.CrossRefPubMed Friedman SR, Southwell M, Bueno R, Paone D, Byrne J, Crofts N. Harm reduction—a historical view from the left. International Journal of Drug Policy. 2001;12(1):3–14.CrossRefPubMed
32.
go back to reference Buchanan D, Shaw S, Ford A, Singer M. Empirical science meets moral panic: an analysis of the politics of needle exchange. J Public Health Policy. 2003:427–44. Buchanan D, Shaw S, Ford A, Singer M. Empirical science meets moral panic: an analysis of the politics of needle exchange. J Public Health Policy. 2003:427–44.
36.
go back to reference Taussig JA, Weinstein B, Burris S, Jones TS. Syringe laws and pharmacy regulations are structural constraints on HIV prevention in the US. AIDS. 2000;14:S47–51.CrossRefPubMed Taussig JA, Weinstein B, Burris S, Jones TS. Syringe laws and pharmacy regulations are structural constraints on HIV prevention in the US. AIDS. 2000;14:S47–51.CrossRefPubMed
37.
go back to reference Beletsky L, Cochrane J, Sawyer AL, Serio-Chapman C, Smelyanskaya M, Han J, et al. Police encounters among needle exchange clients in Baltimore: drug law enforcement as a structural determinant of health. Am J Public Health. 2015;105(9):1872–9.CrossRefPubMedPubMedCentral Beletsky L, Cochrane J, Sawyer AL, Serio-Chapman C, Smelyanskaya M, Han J, et al. Police encounters among needle exchange clients in Baltimore: drug law enforcement as a structural determinant of health. Am J Public Health. 2015;105(9):1872–9.CrossRefPubMedPubMedCentral
38.
go back to reference Bramson H, Des Jarlais DC, Arasteh K, Nugent A, Guardino V, Feelemyer J, et al. State laws, syringe exchange, and HIV among persons who inject drugs in the United States: history and effectiveness. J Public Health Policy. 2015;36(2):212–30.CrossRefPubMed Bramson H, Des Jarlais DC, Arasteh K, Nugent A, Guardino V, Feelemyer J, et al. State laws, syringe exchange, and HIV among persons who inject drugs in the United States: history and effectiveness. J Public Health Policy. 2015;36(2):212–30.CrossRefPubMed
42.
go back to reference Kerr T, Small W, Wood E. The public health and social impacts of drug market enforcement: a review of the evidence. International journal of drug policy. 2005;16(4):210–20.CrossRef Kerr T, Small W, Wood E. The public health and social impacts of drug market enforcement: a review of the evidence. International journal of drug policy. 2005;16(4):210–20.CrossRef
43.
go back to reference Burris S, Blankenship KM, Donoghoe M, Sherman S, Vernick JS, Case P, et al. Addressing the “risk environment” for injection drug users: the mysterious case of the missing cop. The Milbank Quarterly. 2004;82(1):125–56.CrossRefPubMedPubMedCentral Burris S, Blankenship KM, Donoghoe M, Sherman S, Vernick JS, Case P, et al. Addressing the “risk environment” for injection drug users: the mysterious case of the missing cop. The Milbank Quarterly. 2004;82(1):125–56.CrossRefPubMedPubMedCentral
44.
go back to reference Cooper H, Moore L, Gruskin S, Krieger N. The impact of a police drug crackdown on drug injectors’ ability to practice harm reduction: a qualitative study. Soc Sci Med. 2005;61(3):673–84.CrossRefPubMed Cooper H, Moore L, Gruskin S, Krieger N. The impact of a police drug crackdown on drug injectors’ ability to practice harm reduction: a qualitative study. Soc Sci Med. 2005;61(3):673–84.CrossRefPubMed
45.
go back to reference Bluthenthal RN, Ridgeway G, Schell T, Anderson R, Flynn NM, Kral AH. Examination of the association between syringe exchange program (SEP) dispensation policy and SEP client-level syringe coverage among injection drug users. Addiction. 2007;102(4):638–46.CrossRefPubMed Bluthenthal RN, Ridgeway G, Schell T, Anderson R, Flynn NM, Kral AH. Examination of the association between syringe exchange program (SEP) dispensation policy and SEP client-level syringe coverage among injection drug users. Addiction. 2007;102(4):638–46.CrossRefPubMed
46.
go back to reference Bluthenthal RN, Malik R, Grau LE, Singer M, Marshall P, Heimer R. Sterile syringe access conditions and variations in HIV risks among drug injectors in three cities. Addiction. 2004;99:1136–46.CrossRefPubMed Bluthenthal RN, Malik R, Grau LE, Singer M, Marshall P, Heimer R. Sterile syringe access conditions and variations in HIV risks among drug injectors in three cities. Addiction. 2004;99:1136–46.CrossRefPubMed
47.
go back to reference Kral AH, Anderson R, Flynn NM, Bluthenthal RN. Injection risk behaviors among clients of syringe exchange programs with different syringe dispensation policies. Journal of Acquired Immune Deficiency Syndrome. 2004;37:1307–12.CrossRef Kral AH, Anderson R, Flynn NM, Bluthenthal RN. Injection risk behaviors among clients of syringe exchange programs with different syringe dispensation policies. Journal of Acquired Immune Deficiency Syndrome. 2004;37:1307–12.CrossRef
49.
go back to reference Davis CS, Johnston J, de Saxe Zerden L, Clark K, Castillo T, Childs R. Attitudes of North Carolina law enforcement officers toward syringe decriminalization. Drug Alcohol Depend. 2014;144:265–9.CrossRefPubMedPubMedCentral Davis CS, Johnston J, de Saxe Zerden L, Clark K, Castillo T, Childs R. Attitudes of North Carolina law enforcement officers toward syringe decriminalization. Drug Alcohol Depend. 2014;144:265–9.CrossRefPubMedPubMedCentral
Metadata
Title
Syringe Decriminalization Advocacy in Red States: Lessons from the North Carolina Harm Reduction Coalition
Authors
David H. Cloud
Tessie Castillo
Lauren Brinkley-Rubinstein
Manisha Dubey
Robert Childs
Publication date
01-06-2018
Publisher
Springer US
Published in
Current HIV/AIDS Reports / Issue 3/2018
Print ISSN: 1548-3568
Electronic ISSN: 1548-3576
DOI
https://doi.org/10.1007/s11904-018-0397-9

Other articles of this Issue 3/2018

Current HIV/AIDS Reports 3/2018 Go to the issue

Complications of Antiretroviral Therapy (GA McComsey, Section Editor)

NAFLD and HIV: Do Sex, Race, and Ethnicity Explain HIV-Related Risk?

Complications of Antiretroviral Therapy (GA McComsey, Section Editor)

Continued Interest and Controversy: Vitamin D in HIV

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.